Allogene Therapeutics (ALLO) FCF Margin (2021 - 2026)
Allogene Therapeutics (ALLO) posted FCF Margin of 247518.18% for Q1 2024, up 3.43% sequentially from 256319.05% in Q4 2023, and down 2193818.0% YoY from N/an in Q2 2023.
Powered by 
Analysis
Allogene Therapeutics (ALLO) FCF Margin (2021 - 2026) Analysis & Trends
Allogene Therapeutics has reported FCF Margin for 4 years, with the latest figure at 247518.18% in Q1 2024.
- Quarterly FCF Margin fell 2193818.0% year-over-year to 247518.18% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 891004.55% (down 63922770.0% YoY) and the FY2024 annual result came in at 891004.55%, down 63922770.0% from the prior year.
- FCF Margin advanced to 247518.18% in Q1 2024 per ALLO's latest filing, from 256319.05% in the prior quarter.
- Over five years, FCF Margin peaked at 59.6% in Q4 2021 and troughed at 276713.64% in Q2 2023.
- A 4-year average of 163894.86% and a median of 179843.59% in 2022 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 2776705 bps in 2022, down 24638655 bps in 2022.
- Over 4 years, FCF Margin stood at 59.6% in 2021, then tumbled by 413373 bps to 246446.15% in 2022, then declined by 4 bps to 256319.05% in 2023, then grew by 3 bps to 247518.18% in 2024.
- According to Business Quant data, FCF Margin over the past three periods registered 247518.18%, 256319.05%, and 258227.27% for Q1 2024, Q4 2023, and Q3 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Allogene Therapeutics | 647.99 Mn | 647.99 Mn | - | -689.85% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -689.85% |
| Mar 31, 2024 | -247,518.18% |
| Dec 31, 2023 | -256,609.52% |
| Sep 30, 2023 | -252,463.64% |
| Jun 30, 2023 | -282,477.27% |
| Mar 31, 2023 | -225,580.00% |
| Dec 31, 2022 | -245,338.46% |
| Sep 30, 2022 | -177,325.93% |
| Jun 30, 2022 | -66,707.81% |
| Mar 31, 2022 | -182,951.28% |
| Dec 31, 2021 | -61.03% |
| Sep 30, 2021 | -106,581.63% |
| Jun 30, 2021 | -114,168.18% |
| Mar 31, 2021 | -150.29% |